Korea:229000.KQ

Gencurix Receives Australian Government Approval for Droplex POLE Mutation Test

SEOUL, South Korea, Oct. 12, 2023 /PRNewswire/ -- Gencurix , a cancer molecular diagnostics company, has obtained approval from the Australian Government (The Department of Health and Aged Care, Therapeutic Goods Administration) for its Droplex POLE Mutati...

2023-10-12 06:00 2019

Gencurix Obtains Approval for Companion Diagnostic of Digital PCR-based EGFR Mutation Test

SEOUL, South Korea, June 13, 2023 /PRNewswire/ -- Gencurix , a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2. This product is a companion diagnosti...

2023-06-14 09:00 2068

Gencurix Announces Clinical Research Results At ASCO Demonstrating Outstanding Performance of GenesWellBCT Compared to Global Best-Selling Test, OncotypeDX

SEOUL, South Korea, June 7, 2023 /PRNewswire/ -- Gencurix an nounced the release of clinical research results comparing the accuracy of its breast cancer prognostic test, GenesWellBCT, with OncotypeDX, the globally top-s...

2023-06-07 12:29 2761

Gencurix Announces Clinical Research Results At ASCO 2023 Demonstrating Outstanding Performance of GenesWell BCT, the Company's Breast Cancer Prognostic Test, Compared to Global Best-Selling Test, OncotypeDX

SEOUL, South Korea, June 4, 2023 /PRNewswire/ -- Gencurix (KOSDAQ #229000), a leading provider of cancer molecular diagnostics, announced the release of clinical research results directly comparing the accuracy of its breast cancer prognostic test, GenesW...

2023-06-05 14:37 2761

Gencurix announced Korean and Japanese cancer patients' 15-year follow-up prognostic test clinical results

SEOUL, South Korea, May 9, 2023 /PRNewswire/ -- Gencurix announced clinical results of its prognostic test for breast cancer patients at the Global Breast Cancer Conference 2023. The study, 'Long-term prognostic value of GenesWellBCT score in Asian women ...

2023-05-10 08:00 2685